Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0019829 (Hodgkin's disease)
 30,247 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Immunological surface marker techniques were applied in a study of 29 cases of chronic lymphocytic leumaemia and 22 of non-Hodgkin's lymphoma. Surface marker characteristics distinguished 2 subtypes of B lymphocytes. Chronic lymphocytic leukaemia was a monoclonal proliferation of B lymphocytes which produced spontaneous rosettes with mouse erythrocytes and had faintly immunofluorescent surface immunoglobulin. The majority of non-Hodgkin's lymphomas also had their origin from B lymphocytes but in contrast, this subtype did not show receptors for mouse erythrocytes and their surface immunoglobulin was brightly staining and demonstrated "capping". The clonal origin of nodular lymphomas could also be demonstrated on frozen sections stained for surface immunoglobulin. Two cases of true histiocytic lymphoma were identified. The current information available on surface marker characteristics of the leukaemias and lymphomas is reviewed.
 ...
PMID:Surface marker studies in chronic lymphocytic leukaemia and non-Hodgkin's lymphoma. 39 24

Serum IgE concentrations were determined and IgE turnover studies were performed in control individuals as well as in patients with several disease states. Patients with common variable hypogammaglobulinemia, thymoma and hypogammaglobulinemia, ataxia telangiectasia, and selective IgA deficiency had significantly decreased mean serum IgE concentrations. In turnover studies, this was found to be due to decreased IgE synthesis. In spite of these depressed mean values, some patients with common variable hypogammaglobulinemia had normal serum IgE concentrations and synthetic rates. Patients with the Wiskott-Aldrich syndrome had a significantly elevated mean serum IgE concentration. In one of four patients studied with the turnover technique, a strikingly high IgE concentration was present and was associated with an elevated IgE synthetic rate. Three other patients had both normal serum IgE concentrations and synthetic rates. Patients with chronic lymphocytic leukemia had significantly decreased mean serum concentrations and synthetic rates for IgE. The depressed IgE synthesis was associated with a significantly prolonged IgE half-life. Patients with Hodgkin's disease had significantly increased serum IgE concentrations. One of three patients studied had a high serum IgE concentration and synthetic rate of IgE. The two other patients had normal serum IgE concentrations associated with normal synthetic rates. Finally patients with protein-losing enteropathy or familial hypercatabolic hypoproteinemia had normal IgE concentrations associated with normal IgE metabolic parameters. In these cases, the disorder in the catabolic rate was not severe enough to affect the total amount of circulating IgE because IgE normally has a very high fractional catabolic rate. In general, IgE levels in a variety of disease states were correlated with IgE synthetic rates and abnormalities in the catabolic rate of IgE in disease did not exert an important effect on IgE concentration.
 ...
PMID:The metabolism of IgE in patients with immunodeficiency states and neoplastic conditions. 40 20

Purified lymphocytes from venous blood of sixteen healthy adult subjects, eight patients with chronic lymphocytic leukaemia (CLL) and ten with Hodgkin's disease (HD), were examined for adenosine deaminase (ADA), cytidine deaminase (CDA), purine nucleoside phosphorylase (PNPase) and adenosine monophosphate deaminese (AMPA), after thawing and homogenization. The same cells were examined for the capacity to form E rosettes and to respond to phytohaemagglutinin (PHA) stimulation. In CLL a significant reduction (P less than 0-001) of AMPA, PNPase and ADA activities was observed without variation of CDA. In contrast in HD PNPase, AMPA and CDA were increased (P less than 0-01) while ADA was in the normal range. The E-rosette forming cells were significantly reduced in both diseases and the capacity to respond to PHA-stimulation was strongly impaired in CLL. By this experimental approach it seems possible to demonstrate different states of functional activity of the lymphocytic cells in two diseases characterized by reduced T-cell-mediated immunity.
 ...
PMID:Blood lymphocytes in chronic lymphocytic leukaemia and Hodgkin's disease: Immunological features and enzymes of nucleoside metabolism. 40 69

We have studied the thrombocytopenia of lymphoproliferative disorders using a measurement of membrane-bound IgG by an antiglobulin consumption assay. Nine patients with chronic lymphocytic leukemia (CLL) and thrombocytopenia had increased membrane-bound IgG. Two patients with non-Hodgkins lymphoma and 1 patient with Hodgkins disease also had thrombocytopenia and increased membrane-bound IgG. Five of the patients with CLL had positive direct antiglobulin (Coombs) tests on red cells; of these, 3 patients had hemolytic anemia. In eight of the 9 patients with CLL, thrombocytopenia, and increased platelet-bound-IgG, the platelet count increased with the administration of prednisone or an alkylating agent, with splenectomy, or with a combination of these.
 ...
PMID:Immune thrombocytopenia in lymphoproliferative diseases. 42 6

Fourty-three of 61 patients suffering from low-grade malignant non-Hodgkin's lymphomas according to the Kiel classification were subjected to an intermittent combination chemotherapy with chlorambucil and prednisone. In 12 of 35 evaluable patients a complete remission, in 14 of 35 a partial remission could be achieved. The mean remission time of patients with a complete remission exceeds 16 months, that of patients with a partial remission amounts to more than 8 months. In 9 of 35 cases a remission could not be achieved. As 10 of the 12 patients in whom a complete remission could be obtained are alive, the median survival time in cases of complete remission cannot yet be determined. The hematological toxicity was very low, nausea and lack of appetite were observed in 9 of 35 patients. Three of 35 treated and evaluable patients died, viz., 1 patient with a centroblastic-centrocytic lymphoma and 1 patient with a chronic lymphocytic leukemia died from the sequelae of progression during the chemotherapy of second choice according to the COP regimen. The third patient with a centroblastic-centrocytic lymphoma died from the sequelae of an intrahepatic cholestatic icterus, also during the chemotherapy of second choice according to the COP regimen. In the last-mentioned case, autopsy also confirmed a continuous complete remission of the centroblastic-centrocytic lymphoma.
 ...
PMID:Intermittent combination chemotherapy with chlorambucil and prednisone of low-grade malignant non-Hodgkin's lymphomas according to the Kiel classification. 43 82

Total hemolytic complement (CH50) and eight antigenic fractions of the complement system were determined in 30 patients with hematological neoplasias, distributed into the following groups: six cases of non-Hodgkin's lymphomas (NHL), seven cases of chronic lymphocytic leukemia (CLL), five cases of Hodgkin's disease (HD), seven cases of acute leukemia (AL), three cases of chronic myeloid leukemia (CML) and two cases of multiple myeloma (MM). CH50 was titred accordingly to a modification of the Kabat and Mayer method, C1q, C1s, C3, C4, C5, INHC1, C3A and properdin were determined with specific antisera by Manani and Laurell's techniques. The results obtained showed significant increase in CH50 above normal values in patients with HD, AL, and CML, especially the former, even in early stages. C1s was found to be increased in CML and AL, as well as C3 in CML. C4 is increased in CML and HD. C5 follows a course similar to C4, being also increased CLL and MM. C9 is increased in all groups, except NHL. A significant increase in C3A was found in NHL, HD and AL. There were no significant variations in C1s, INHC1 and properdin in any of the former groups. No correlation was found between clinical course and complement increase. The role of complement in neoplastic disease is discussed.
 ...
PMID:Complement in hematological neoplasias. 47 24

Whereas the contribution of exploratory laparotomy in Hodgkin's disease is well characterized, its value in Non-Hodgkin lymphoma (NHL) is not yet defined. This retrospective analysis of 31 cases is a contribution to the ongoing discussion. Laparotomy/splenectomy (LS) was done in 17 patients for diagnostic reasons and in 14 with therapeutic intent. Perioperative morbidity was low. In 17 cases the NHL had infiltrated the spleen. Indications for therapeutic LS were hemolytic anemia, pancytopenia and excessive lymphocytosis with granulocytopenia. The therapeutic benefit from splenectomy was satisfactory, especially in patients with well-differentiated lymphocytic leukemia of type CLL. In contrast, the diagnostic value of LS was minimal, except in patients with first diagnosis of NHL through LS. There was no change in tumor stage in any case. However, 4 false-negative findings contrast with the rapidly adverse course in these patients. Routine LS in patients with NHL does not appear to be justified, but has its value in NHL with primary abdominal localization. Therapeutic splenectomy is of benefit for the majority of patients, particularly those with CLL.
 ...
PMID:[Diagnostic and therapeutic importance of splenectomy in patients with non-Hodgkin's lymphoma]. 48 11

Issuing from the clinico-prognostic importance of the classification after Kiel of the malignant non-Hodgkin-lymphomas the results of the attempt of a reclassification of positive bioptic findings of the iliac crest judged according to the former German nomenclature are described and discussed after the Kiel classification. In the total material of 725 biopsies 76 positive findings of the marrow were stated in malignant non-Hodgkin-lymphomas, which at 67.1% consist of such with a lower and at 32.9% of such with a high degree of malignity, in which case a strong decrease of the formerly diagnosed CLL is to be seen after reclassification, whereas the immunocytomas render the by far largest proportion. The former malignant reticuloses disappear per definitionem after reclassification and, as it was expected, are broadly distributed. In 112 biopsies which were performed on account of the suspicion of an affection of the marrow in malignant non-Hodgkin-lymphomas the 76 positive findings correspond to a frequency of 67.9%, which, however, must critically be judged, since the case in question are very selected numbers of patients.
 ...
PMID:[Iliac crest biopsy findings in malignant non-Hodgkin lymphoma]. 53 69

The studies were performed to estimate the sensitivity of chronic lymphocytic leukaemia (CLL) lymphocytes (32 patients), non-Hodgkin lymphoma (NCL) lymphocytes (3 patients) and normal human (NH) lymphocytes (20 persons) to antimitotic concentration of colchicine in the conditions of the in vitro Thomson's test. Significant differences were observed in this sensitivity test: for CLL lymphocytes the mean values was 79%, for N-HL-lymphocytes 37%, for NH-lymphocytes--12%. These data show the possibility of practical use of Thomson's test in differential diagnosis of increased lymphocytosis. A quantitative heterogeneity of colchicine sensitive (pathological) and non-sensitive ("normal") CLL lymphocyte populations was observed among different CLL patients. There was no correlation between the proportion of the above populations and the patient's age, duration of illness and the magnitude of total lymphocytosis.
 ...
PMID:[Thomson's colchicine test in differential diagnosis of lymphocytic leukemia and non-Hodgkin lymphoma]. 53 54

149 patients with non Hodgkin lymphomas (NHL) were observed at the III. Medical Department of the Hanusch Hospital during 1972--1978. 15 out of 106 patients with low malignant NHL had autoimmune hemolytic anemia (AHA). None of the patients with high malignant NHL showed evidence of hemolysis. In 10 cases AHA was diagnosed together with the lymphoproliferative disease. In 4 cases diagnosis of AHA and NHL was established at the same time and in only 1 patient diagnosis of AHA preceded the lymphatic disease. All patients had distinct signs of hemolysis with moderate to severe anemia. 4 patients with immunocytic lymphomas had IgM paraproteins and an elevation of gamma-globulins, all other patients had mild to severe hypogammaglobulinemia. Therapy in all cases consisted of corticosteroids and cytostatics (Chlorambucil, Cyclophosphamide). In none of our cases splenectomy was performed. AHA seems to be a bad prognostic factor in patients with chronic lymphocytic leukemia. Survival time in patients with chronic lymphocytic leukemia and AHA was 18 months shorter than in all other patients suffering from chronic lymphocytic leukemia.
 ...
PMID:[Accompanying hemolysis in lymphoproliferative diseases]. 55 12


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>